Bay Pharma

Bay Pharma is committed to accelerating Australia’s transition to a smoke-free future by providing high quality therapeutic vaping solutions. By integrating pharmaceutical-grade standards and rigorous supply-chain processes, Bay Pharma delivers trusted, research backed solutions for smoking cessation and harm reduction.

The company prioritises product innovation, pharmaceutical formulation, clinical research and quality assurance to advance safety and effectiveness. Through these efforts, Bay Pharma aims to support healthcare providers and patients with credible alternatives, contributing to a healthier Australia.

Year founded: 2022
Headquarters located: Sydney, NSW

Innovation in smoking cessation products

Bay Pharma is dedicated to transforming smoking cessation through the use of pharmaceutical-grade therapeutic products. By integrating advanced technology with rigorous safety and quality standards, Bay Pharma provides trusted solutions that can support harm reduction and smoking cessation efforts.

Bay Pharma is committed to a health-first approach, ensuring its products meet and exceed Australian regulatory standards. This includes full compliance with TGO-110, as well as the forthcoming changes to regulation from 1 July 2025. They deliver scientifically backed alternatives designed to reduce the harms of smoking while maintaining strict measures to prevent access by youth and non-smokers.

Through continuous research, collaboration with medical and scientific experts and a commitment to innovation, Bay Pharma remains at the forefront of smoking cessation technology. By prioritising safety, efficacy and responsible access, the company is helping pave the way for a smoke-free Australia.